Literature DB >> 24351755

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Katharina Richard1, Barbara J Mann, Lenea Stocker, Eileen M Barry, Aiping Qin, Leah E Cole, Matthew T Hurley, Robert K Ernst, Suzanne M Michalek, Daniel C Stein, Philip Deshong, Stefanie N Vogel.   

Abstract

Francisella tularensis is a Gram-negative immune-evasive coccobacillus that causes tularemia in humans and animals. A safe and efficacious vaccine that is protective against multiple F. tularensis strains has yet to be developed. In this study, we tested a novel vaccine approach using artificial pathogens, synthetic nanoparticles made from catanionic surfactant vesicles that are functionalized by the incorporation of either F. tularensis type B live vaccine strain (F. tularensis LVS [LVS-V]) or F. tularensis type A Schu S4 strain (F. tularensis Schu S4 [Schu S4-V]) components. The immunization of C57BL/6 mice with "bare" vesicles, which did not express F. tularensis components, partially protected against F. tularensis LVS, presumably through activation of the innate immune response, and yet it failed to protect against the F. tularensis Schu S4 strain. In contrast, immunization with LVS-V fully protected mice against intraperitoneal (i.p.) F. tularensis LVS challenge, while immunization of mice with either LVS-V or Schu S4-V partially protected C57BL/6 mice against an intranasal (i.n.) F. tularensis Schu S4 challenge and significantly increased the mean time to death for nonsurvivors, particularly following the i.n. and heterologous (i.e., i.p./i.n.) routes of immunization. LVS-V immunization, but not immunization with empty vesicles, elicited high levels of IgG against nonlipopolysaccharide (non-LPS) epitopes that were increased after F. tularensis LVS challenge and significantly increased early cytokine production. Antisera from LVS-V-immunized mice conferred passive protection against challenge with F. tularensis LVS. Together, these data indicate that functionalized catanionic surfactant vesicles represent an important and novel tool for the development of a safe and effective F. tularensis subunit vaccine and may be applicable for use with other pathogens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24351755      PMCID: PMC3910930          DOI: 10.1128/CVI.00738-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  76 in total

1.  Spontaneous vesicle formation in aqueous mixtures of single-tailed surfactants.

Authors:  E W Kaler; A K Murthy; B E Rodriguez; J A Zasadzinski
Journal:  Science       Date:  1989-09-22       Impact factor: 47.728

2.  Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors.

Authors:  Adeline M Hajjar; Megan D Harvey; Scott A Shaffer; David R Goodlett; Anders Sjöstedt; Helen Edebro; Mats Forsman; Mona Byström; Mark Pelletier; Christopher B Wilson; Samuel I Miller; Shawn J Skerrett; Robert K Ernst
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

3.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

4.  Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.

Authors:  Tara L Kieffer; Siobhan Cowley; Francis E Nano; Karen L Elkins
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

5.  Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors:  J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

6.  A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis.

Authors:  Deborah D Crane; Shayna L Warner; Catharine M Bosio
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

7.  Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns.

Authors:  Chris A Mares; Sandra S Ojeda; Elizabeth G Morris; Qun Li; Judy M Teale
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

8.  Cationic-anionic vesicle templating from fluorocarbon/fluorocarbon and hydrocarbon/fluorocarbon surfactants.

Authors:  Vivian A Ojogun; Hans-Joachim Lehmler; Barbara L Knutson
Journal:  J Colloid Interface Sci       Date:  2009-06-14       Impact factor: 8.128

Review 9.  Towards proteome database of Francisella tularensis.

Authors:  Martin Hubálek; Lenka Hernychová; Jana Havlasová; Irena Kasalová; Vera Neubauerová; Jirí Stulík; Ales Macela; Margaretha Lundqvist; Pär Larsson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-04-05       Impact factor: 3.205

10.  Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination.

Authors:  Dedeke Rockx-Brouwer; Audrey Chong; Tara D Wehrly; Robert Child; Deborah D Crane; Jean Celli; Catharine M Bosio
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

View more
  8 in total

1.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

2.  Dissociation of TRIF bias and adjuvanticity.

Authors:  Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel
Journal:  Vaccine       Date:  2020-05-07       Impact factor: 3.641

Review 3.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

Review 4.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

Review 5.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

6.  An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.

Authors:  Ahd A Mansour; Sukalyani Banik; Ragavan V Suresh; Hardeep Kaur; Meenakshi Malik; Alison A McCormick; Chandra S Bakshi
Journal:  Front Microbiol       Date:  2018-06-05       Impact factor: 5.640

Review 7.  Adaptive Immunity to Francisella tularensis and Considerations for Vaccine Development.

Authors:  Lydia M Roberts; Daniel A Powell; Jeffrey A Frelinger
Journal:  Front Cell Infect Microbiol       Date:  2018-04-06       Impact factor: 5.293

Review 8.  Comparative review of Francisella tularensis and Francisella novicida.

Authors:  Luke C Kingry; Jeannine M Petersen
Journal:  Front Cell Infect Microbiol       Date:  2014-03-13       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.